- Home
- AGEN vs IMPP Comparison
AGEN vs IMPP Comparison
Compare AGEN & IMPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- IMPP
- Stock Information
- Founded
- AGEN 1994
- IMPP 1981
- Country
- AGEN United States
- IMPP Greece
- Employees
- AGEN N/A
- IMPP N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- IMPP Marine Transportation
- Sector
- AGEN Health Care
- IMPP Consumer Discretionary
- Exchange
- AGEN Nasdaq
- IMPP Nasdaq
- Market Cap
- AGEN 87.7M
- IMPP 95.7M
- IPO Year
- AGEN 2000
- IMPP N/A
- Fundamental
- Price
- AGEN $5.16
- IMPP $3.09
- Analyst Decision
- AGEN Buy
- IMPP
- Analyst Count
- AGEN 4
- IMPP 0
- Target Price
- AGEN $13.00
- IMPP N/A
- AVG Volume (30 Days)
- AGEN 1.6M
- IMPP 185.0K
- Earning Date
- AGEN 08-07-2025
- IMPP 05-23-2025
- Dividend Yield
- AGEN N/A
- IMPP N/A
- EPS Growth
- AGEN N/A
- IMPP N/A
- EPS
- AGEN N/A
- IMPP 1.21
- Revenue
- AGEN $99,524,000.00
- IMPP $138,368,325.00
- Revenue This Year
- AGEN $14.49
- IMPP $8.79
- Revenue Next Year
- AGEN N/A
- IMPP $40.11
- P/E Ratio
- AGEN N/A
- IMPP $2.55
- Revenue Growth
- AGEN N/A
- IMPP N/A
- 52 Week Low
- AGEN $1.38
- IMPP $2.12
- 52 Week High
- AGEN $18.74
- IMPP $4.55
- Technical
- Relative Strength Index (RSI)
- AGEN 62.39
- IMPP 65.82
- Support Level
- AGEN $5.06
- IMPP $2.73
- Resistance Level
- AGEN $6.35
- IMPP $3.19
- Average True Range (ATR)
- AGEN 0.59
- IMPP 0.18
- MACD
- AGEN 0.12
- IMPP 0.02
- Stochastic Oscillator
- AGEN 65.00
- IMPP 86.49
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.